---
title: "Neumora Therapeutics, Inc. (NMRA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NMRA.US.md"
symbol: "NMRA.US"
name: "Neumora Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-06-19T09:04:08.277Z"
locales:
  - [en](https://longbridge.com/en/quote/NMRA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NMRA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NMRA.US.md)
---

# Neumora Therapeutics, Inc. (NMRA.US)

## Company Overview

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company’s preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson’s Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.neumoratx.com](https://www.neumoratx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.24 | 116 | - | - | - |
| PB | 3.90 | 128 | 3.51 | 2.62 | 1.47 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-18T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 56% |
| Overweight | 2 | 22% |
| Hold | 1 | 11% |
| Underweight | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.51 |
| Highest Target | 18.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NMRA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NMRA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NMRA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NMRA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**